CureLab Oncology Seeks to Revolutionize Chronic Pain Management with Novel p62-Based Therapy
November 14, 2024
Can a polarized biomedical community reform drug development policies while maintaining nuance and moderation?
February 6, 2025CureLab Oncology highlighted in Labiotech's deep dive on ovarian cancer vaccines
In an in-depth feature published by Labiotech.eu, journalist Helen Albert explores the burgeoning field of ovarian cancer vaccines, focusing on how innovative therapies are making strides in addressing this challenging disease. CureLab Oncology’s Elenagen™ is prominently featured among the pioneering efforts, alongside other notable players like BioNTech. Albert examines how Elenagen is designed to modulate the immune system, aiming to combat ovarian cancer more effectively.
The article highlights the unique approach of Elenagen™, stating:
“CureLab Oncology is taking a novel approach to ovarian cancer treatment by targeting the immune system’s ability to suppress tumor growth.”
CureLab Oncology founder and CEO Dr. Alexander Shneider is also quoted:
“The p62 protein is present in all cells. Cancer cells, however, cannot survive without it. Moreover, cancer cells overexpress p62, which protects them from chemo- and radiation therapy. We can induce an immune response when we inject a DNA or RNA drug with a gene encoding p62 into a muscle. Then, a vaccine-induced immune response would find and eliminate in the body the cells that express elevated levels of p62 – the cancer cells."
Albert also emphasizes the broader significance of vaccine-based cancer therapies:
“Cancer vaccines are increasingly being recognized as an important tool in the fight against cancers, especially those like ovarian cancer where current treatments have limited success.”
The inclusion of CureLab Oncology in this analysis by a leading biotechnology publication highlights the company's growing influence and the promise of its groundbreaking Elenagen™ therapy. It positions CureLab Oncology as a key player in the development of innovative cancer vaccines, alongside industry leaders.
